Inflammatix向美国军方运送 TriVerity™检测试剂盒和 Myrna™仪器-动脉网

Inflammatix Ships TriVerity™ Test Cartridges and Myrna™ Instruments to the U.S. Military

CISION 等信源发布 2025-03-25 19:30



可切换为仅中文







The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) purchases TriVerity Test System to evaluate for use in the field

联合项目执行办公室（JPEO-CBRND）购买了TriVerity测试系统，用于评估其在战场上的使用。

Inflammatix receives an initial

Inflammatix收到初步的

$1.2 million

120万美元

to cover the first phase of system evaluation, with future phase options worth up to

涵盖系统评估的第一阶段，未来阶段选项的价值高达

$20.8 million

2080万美元

SUNNYVALE, Calif.

加利福尼亚州桑尼维尔

，

March 25, 2025

2025年3月25日

/PRNewswire/ -- Inflammatix, a pioneering molecular diagnostics company, today announced the shipment of TriVerity™ cartridges and Myrna™ instruments to the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to facilitate the differentiation of bacterial infections, viral infections, and non-infectious illness.

/PRENewswire/ -- 分子诊断领域的先驱企业Inflammatix今天宣布，已向化学、生物、放射性和核防御联合项目执行办公室（JPEO-CBRND）运送了TriVerity™试剂盒和Myrna™仪器，以帮助区分细菌感染、病毒感染和非传染性疾病。

In the first phase of its agreement with Inflammatix, the JPEO-CBRND, which manages the acquisition, fielding and sustainment of chemical, biological, radiological, and nuclear (CBRN) defense capabilities to the joint force, will assess the viability of TriVerity cartridges and Myrna™ instruments for field use.

在与Inflammatix协议的第一阶段，负责为联合部队管理化学、生物、放射性和核（CBRN）防御能力的采购、部署和维护的JPEO-CBRND将评估TriVerity卡盒和Myrna™仪器在野外使用的可行性。

The initial shipment, for which Inflammatix is to receive more than .

初始装运，Inflammatix将收到超过。

$1.2 million

120万美元

, is part of a JPEO-CBRND contract worth up to

，是价值高达多少的JPEO-CBRND合同的一部分

$20.8 million

2080万美元

if all options are exercised.

如果行使所有选项。

TriVerity, Inflammatix's flagship product, is a rapid blood test that measures the expression levels of 29 genes involved in the immune response associated with acute infection status and illness severity. The device, which was cleared for clinical use by the U.S. Food and Drug Administration (FDA) on .

TriVerity是Inflammatix的旗舰产品，是一种快速血液检测，可测量与急性感染状态和疾病严重程度相关的免疫反应中涉及的29个基因的表达水平。该设备已获得美国食品药品监督管理局（FDA）的临床使用批准。

January 10, 2025

2025年1月10日

, is designed to facilitate management of patients presenting with suspected acute infection or sepsis. As part of the first phase of the contract, the JPEO-CBRND will conduct cybersecurity analyses of TriVerity and evaluate the system's suitability in a deployed military setting where personnel may be confronted with biothreat and endemic infectious diseases.

，旨在帮助管理疑似急性感染或脓毒症患者的诊疗。作为合同第一阶段的一部分，JPEO-CBRND将对TriVerity进行网络安全分析，并评估该系统在部署的军事环境中的适用性，因为在军事环境中，人员可能面临生物威胁和地方性传染病。

The remainder of the contract grants the JPEO-CBRND the option to ruggedize and/or improve the Myrna instrument and enhance the test system for use in a field-forward setting..

合同的其余部分授予JPEO-CBRND选择权，以 ruggedize 和/或改进 Myrna 仪器，并增强测试系统，以便在前方场地使用。

'We are pleased that the JPEO-CBRND has chosen to evaluate our TriVerity Test System, including TriVerity cartridges and the Myrna instrument, for military use,' said Dr.

“我们很高兴JPEO-CBRND选择评估我们的TriVerity测试系统，包括TriVerity试剂盒和Myrna仪器，用于军事用途，”博士表示。

Timothy Sweeney

蒂莫西·斯威尼

, CEO and co-founder of Inflammatix. 'TriVerity's ability to rapidly rule in and rule out bacterial infection, viral infection and illness severity has the potential to streamline triage for our Armed Forces in forward environments. We are confident that this robust test system, which we have built for routine clinical use, can be modified and optimized for use in military settings.'.

，Inflammatix的首席执行官兼联合创始人。“TriVerity能够快速判断细菌感染、病毒感染及疾病严重程度的能力，有可能简化前线环境中武装部队的分诊工作。我们相信，这个为常规临床使用而构建的强大测试系统可以进行修改和优化，以适用于军事环境。”

The JPEO-CBRND contract comes at a time of increasing risk of acute infection and sepsis in the U.S. military. Data suggest that soldiers in combat zones are at elevated risk of respiratory infections, with an incidence nearly three times as great as that in the adult civilian population; more than 40% of soldiers' respiratory illnesses are attributed to unknown causative agents..

JPEO-CBRND合同签署之际，正值美国军队中急性感染和败血症风险日益增加之时。数据显示，战斗区域的士兵患呼吸道感染的风险较高，其发病率几乎是成年平民群体的三倍；超过40%的士兵呼吸道疾病由未知病原体引起。

In an analysis of sepsis hospitalization data of active military personnel from

在对现役军人的脓毒症住院数据进行分析时

January 1, 2011

2011年1月1日

, to

，到

December 31, 2020

2020年12月31日

, researchers reported an overall incidence of 39.8 hospitalizations per 100,000 person-years. The annual incidence increased 64% from 2011 through 2019, then dropped in 2020, during the COVID-19 pandemic.

研究人员报告的总体发病率为每10万人年39.8例住院。2011年至2019年间，年发病率增加了64%，然后在2020年新冠疫情大流行期间下降。

These trends highlight the need for a portable, well-built diagnostic test that can rapidly and reliably detect the presence and assess the severity of infection under battlefield conditions.

这些趋势突显了对一种便携、构造良好的诊断测试的需求，这种测试能够在战场条件下快速且可靠地检测感染的存在并评估其严重程度。

Disclaimer: The views and opinions of authors expressed herein do not necessarily state or reflect those of

免责声明：此处表达的作者观点和意见不一定陈述或反映那些

the United States

美国

government and reference herein to any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise, does not constitute or imply its endorsement, recommendation, or favoring by the U.S. government and shall not be used for advertising or product endorsement purposes..

政府提及任何特定商业产品、工艺或服务的名称、商标、制造商或其他方式，并不构成或暗示美国政府对其的认可、推荐或支持，也不得用于广告或产品代言用途。

About the TriVerity™ Test System

关于TriVerity™测试系统

The TriVerity™ Test System ('TriVerity'), Inflammatix's flagship

TriVerity™ 测试系统（“TriVerity”），Inflammatix 的旗舰产品

in vitro

体外

diagnostic (IVD) test, includes the TriVerity cartridge and the Myrna™ instrument. TriVerity incorporates a panel of 29 patient messenger RNAs (mRNAs) to rapidly 'read' the body's immune response to infection using machine learning-derived algorithms. TriVerity shows the likelihood of a bacterial infection, a viral infection, and illness severity in adult patients with suspected acute infection or sepsis that present to emergency departments.

诊断（IVD）测试，包括TriVerity卡盒和Myrna™仪器。TriVerity整合了一个包含29种患者信使RNA（mRNA）的面板，利用机器学习衍生的算法快速“读取”身体对感染的免疫反应。TriVerity显示成年患者疑似急性感染或败血症时，细菌感染、病毒感染的可能性以及疾病严重程度，适用于急诊科就诊的患者。

TriVerity empowers physicians to confidently make care decisions, which could influence the selection of antimicrobial therapy, focused workups with judicious laboratory and imaging orders, and patient admission or discharge disposition..

TriVerity赋能医生自信地做出诊疗决策，这些决策可能影响抗菌治疗的选择、有针对性的检查以及合理的实验室和影像学检查要求，还有患者的入院或出院安排。

About Inflammatix

关于Inflammatix

Inflammatix, Inc., based in

Inflammatix公司，总部位于

Sunnyvale, California

加利福尼亚州桑尼维尔

, USA, is revolutionizing molecular diagnostics with machine-learning-powered technology to rapidly read a patient's immune response. Our innovative diagnostics aim to improve patient care and tackle significant public health challenges. Designed for our advanced sample-to-answer isothermal instrument platform, our tests bring the power of precision medicine to the point of care.

美国正在通过机器学习技术彻底改变分子诊断，以快速读取患者的免疫反应。我们创新的诊断方法旨在改善患者护理并应对重大的公共卫生挑战。我们的测试专为先进的样本到结果的一体化等温仪器平台设计，将精准医疗的力量带到护理点。

The company's funders include Khosla Ventures, Northpond Ventures, Think.Health Ventures, D1 Capital, Iberis Capital, and Vesalius BioCapital, and the Stanford-StartX Fund. For more information, please visit .

公司的资助者包括Khosla Ventures、Northpond Ventures、Think.Health Ventures、D1 Capital、Iberis Capital、Vesalius BioCapital以及斯坦福StartX基金。欲了解更多信息，请访问。

www.inflammatix.com

and follow the company on

并关注公司

领英

and

和

(formerly Twitter) at @Inflammatix_Inc).

（前身为Twitter）@Inflammatix_Inc）。

Inflammatix product development has been funded in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; and the Biomedical Advanced Research and Development Authority, under contract numbers 75A50119C00034, 75A50119C00044, and 75A50122C00069..

Inflammatix 的产品开发部分得到了美国卫生与公众服务部、战略准备与响应管理局以及生物医学高级研究与发展管理局的联邦资金支持，合同编号分别为 75A50119C00034、75A50119C00044 和 75A50122C00069。

TriVerity, Myrna, and Inflammatix are trademarks of Inflammatix, Inc. in the U.S. and other countries and regions.

TriVerity、Myrna 和 Inflammatix 是 Inflammatix, Inc. 在美国及其他国家和地区的商标。

References

参考文献

Korzeniewski K, Nitsch-Osuch A, Konior M, Lass A. Respiratory tract infections in the military environment.

Korzeniewski K、Nitsch-Osuch A、Konior M、Lass A。军队环境中的呼吸道感染。

Respir Physiol Neurobiol.

呼吸生理学与神经生物学。

2014;209:76-80.

2014；209：76-80。

Snitchler CL, Patel DM, Stahlman SL, Chauhan AV,